Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
canagliflozin + glp-1 analogue
- Development stage
- Preclinical
- Lead developer
- Janssen Research & Development
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Canagliflozin + glp-1 analogue is a combination therapy consisting of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin and a glucagon-like peptide 1 (GLP-1) receptor analogue. Canagliflozin inhibits SGLT2 in the proximal renal tubules, resulting in reduced glucose reabsorption and increased urinary glucose excretion. GLP-1 analogues act as agonists at the glucagon-like peptide 1 receptor, enhancing glucose-dependent insulin secretion, lowering glucagon secretion, slowing gastric emptying, and promoting satiety. This combination is used primarily for type 2 diabetes, offering additive (possibly synergistic) effects on glycemic control, weight loss, systolic blood pressure reduction, and improvement of cardiovascular and renal outcomes over monotherapy. Common adverse events may include gastrointestinal symptoms, genitourinary infections, and low risk of hypoglycemia, with some mitigation of adverse metabolic effects when combined.
- Other names
- canagliflozin plus glp-1 analogue
02
Targets
SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)GLP1R (GLP-1R)
Beyond the preview
Go deeper on canagliflozin + glp-1 analogue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on canagliflozin + glp-1 analogue.